{"id":"33ec98c0-3c43-443e-869a-265839a0fd13","VespaId":"conexiant-53827cc0-990a-4c4b-b8e7-cc00628e8e9b","Title":"Indeterminate Thyroid Nodule Size May Predict RFA Success ","RewrittenTitle":"","Description":"In a functionally screened cohort, there was an 85% likelihood of being free of local treatment failure at 3 years, with outcomes favoring nodules smaller than 3 cm.","BodyContent":"Patients with indeterminate thyroid nodules who underwent radiofrequency ablation following functional imaging screening experienced sustained nodule reduction and symptom improvement, with a high probability of remaining free of local treatment failure at 3 years, according to a retrospective cohort study. Researchers evaluated 109 patients with Bethesda category III or IV thyroid nodules treated with radiofrequency ablation (RFA) in Taiwan between 2018 and 2024. All of the patients had indeterminate cytology on at least two assessments and underwent preprocedural risk stratification with technetium-99m–methoxyisobutylisonitrile scintigraphy or fluorine-18–fluorodeoxyglucose positron emission tomography. The cohort consisted of patients who met predefined imaging criteria and elected RFA after declining surgery. The median follow-up was 2.2 years. The primary outcome was local treatment failure, defined as nodule regrowth, an increase in vital volume, or persistent indeterminate cytology during follow-up. The secondary outcome was complete disappearance of the treated nodule. The researchers also assessed volume reduction, symptom and cosmetic scores, and thyroid-related laboratory measures. Local treatment failure occurred in about 14% (n = 15/109) of the patients. The estimated probability of remaining free of local treatment failure at 3 years was 85%. Complete disappearance of the nodule occurred in 8% (n = 9) of the patients, corresponding to a 3-year cumulative incidence of 7%. Most of the local treatment failures were related to persistent indeterminate cytology. For instance, 10 of the patients had repeat Bethesda III or IV findings on follow-up fine-needle aspiration, 5 of them experienced nodule regrowth, and 1 of them had an increase in vital volume. Among those with regrowth, 3 patients underwent repeat RFA and 2 patients continued active surveillance. No patient required surgery during follow-up. Nodule volume declined progressively throughout follow-up. Volume reduction reached 56% at 3 months, 75% at 1 year, and 91% at 3 years. Symptom and cosmetic scores also improved over time. Free thyroxine and thyroglobulin levels decreased; while total triiodothyronine, thyroid-stimulating hormone, and antithyroid antibody levels remained stable. Baseline nodule size was the strongest predictor of outcomes. Larger nodules were more likely to experience local treatment failure and less likely to disappear completely. The researchers reported that 93% of nodules smaller than 3 cm remained free of local treatment failure at 3 years. No nodule larger than 2.1 cm achieved complete disappearance during follow-up. Safety outcomes were generally favorable. Five of the patients experienced vocal cord palsy–related hoarseness. Four recovered completely within 3 months, while 1 patient had persistent but improving vocal cord dysfunction and was classified as having a major complication. No local or distant metastases were observed during follow-up. Among the 97 patients who underwent posttreatment fine-needle aspiration, 0% had Bethesda category V or VI cytology. The researchers stated that the findings should be interpreted within the context of several limitations. The study was retrospective and conducted at a single center. The cohort was highly selected, including only patients who met functional imaging criteria and chose RFA rather than surgery. In addition, the researchers did not directly compare outcomes with surgery, active surveillance, or patients who did not undergo imaging-based screening. They noted that the proposed nodule-size thresholds require external validation and that longer follow-up is needed to assess long-term outcomes. In their conclusion, wrote lead study author Ling-Chieh Shih, of Kaohsiung Chang Gung Memorial Hospital in Taiwan, and colleagues wrote that “RFA demonstrated acceptable outcomes with volume reduction and symptom relief, particularly in patients with nodules [less than] 3 cm.” They added that baseline nodule diameter “may serve as a practical factor for patient selection and counseling,” wrote lead study author Ling-Chieh Shih, of the Department of Diagnostic Radiology at the Kaohsiung Chang Gung Memorial Hospital at the Chang Gung University College of Medicine in Taiwan, and colleagues. The study authors reported no conflicts of interest. No funding was reported. Source: Korean Journal of Radiology","Url":"https://news.mdspire.com/radiology/articles/indeterminate-thyroid-nodule-size-may-predict-rfa-success/","ContentType":"article","ThumbnailImgUrl":"https://news.mdspire.com/media/zkmkn4q0/rfa.jpg","PubName":"MDSpire News","LastUpdated":"2026-06-17T21:35:35Z","PublishDate":"2026-06-17T00:00:00Z","SourceId":"53827cc0-990a-4c4b-b8e7-cc00628e8e9b","IsSyndicated":true,"SyndicateExternally":true,"IsOurContent":true,"TranscriptUrl":"","Transcript":"","Volume":"","Issue":"","IsSponsored":false,"Authors":["Andrea Surnit"],"Categories":[{"Label":"Categories","Options":["From The Journals"]}],"AIContent":{"Teaser":"","Summary":"

Objective:

To evaluate the outcomes of radiofrequency ablation (RFA) in patients with indeterminate thyroid nodules.

Approach:

Key Findings:

Local treatment failure occurred in about 14% of patients, with most related to persistent indeterminate cytology.
Estimated probability of remaining free of local treatment failure at 3 years was 85%.
Complete disappearance of the nodule occurred in 8% of patients.
Nodule volume reduction reached 56% at 3 months, 75% at 1 year, and 91% at 3 years.
Baseline nodule size was the strongest predictor of outcomes.

Interpretation:

Limitations:

Study was retrospective and conducted at a single center.
Cohort was highly selected, including only patients who met functional imaging criteria.
No direct comparison with surgery or active surveillance.

Conclusion:

RFA demonstrated acceptable outcomes with volume reduction and symptom relief, particularly in patients with nodules less than 3 cm, as stated by the study authors.

Sources:

Korean Journal of Radiology

Clinical Scorecard: Indeterminate Thyroid Nodule Size May Predict RFA Success

At a Glance

Category	Detail
Condition
Key Mechanisms	Radiofrequency ablation (RFA) following imaging screening as per study findings
Target Population
Care Setting

Key Highlights

85% probability of remaining free of local treatment failure at 3 years (source needed)
Local treatment failure occurred in about 14% of patients (source needed)
Volume reduction reached 91% at 3 years (source needed)
93% of nodules smaller than 3 cm remained free of local treatment failure (source needed)
No local or distant metastases observed during follow-up (source needed)

Guideline-Based Recommendations

Diagnosis

Preprocedural risk stratification with imaging techniques (source needed)

Management

Radiofrequency ablation for patients declining surgery (source needed)

Monitoring & Follow-up

Follow-up fine-needle aspiration to assess cytology (source needed)

Risks

Potential vocal cord palsy-related hoarseness (source needed)

Patient & Prescribing Data

109 patients with indeterminate thyroid nodules

Larger nodules more likely to experience local treatment failure

Clinical Best Practices

Consider baseline nodule diameter for patient selection and counseling (source needed)
Monitor symptom and cosmetic scores over time (source needed)

Related Resources & Content

Korean Journal of Radiology

Conexiant's News Site Is Now MDSpire News.

Trending Now

FDA Approves New Iohexol Vials

Trending Now

Find topic & conditions by first letter

Compendium

Inside Dental Hygiene

Inside Dentistry

ADA News

CDE World

New Dentist News

MDSpire News

AACE Endocrinology AI

MDSpire News

GI & Hepatology News

The ASCO Post

JADPRO

JNCCN

JNCCN 360

ASCO AI in Oncology

Glaucoma Physician

Ophthalmology Management

Retinal Physician

The Ophthalmologist

Contact Lens Spectrum

Eyecare Business

Optometric Management

The Pathologist

The Medicine Maker

The Analytical Scientist

Indeterminate Thyroid Nodule Size May Predict RFA Success

Daily News

Recommendations